{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:44:56Z","timestamp":1778233496949,"version":"3.51.4"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/mcg.0b013e3182702f2b","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T07:41:06Z","timestamp":1353570066000},"page":"339-345","source":"Crossref","is-referenced-by-count":45,"title":["Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn\u2019s Disease"],"prefix":"10.1097","volume":"47","author":[{"given":"Jill P.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra I.","family":"Bingaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Mauger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210305","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohns disease in children.","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"R2-11-20210305","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(99)00442-0","article-title":"Antibodies to tumour necrosis factor alpha as treatment for Crohns disease.","volume":"355","author":"Bell","year":"2000","journal-title":"Lancet"},{"key":"R3-11-20210305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"R4-11-20210305","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease.","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-11-20210305","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R6-11-20210305","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2008.163279","article-title":"Hepatosplenic T cell lymphoma in inflammatory bowel disease.","volume":"57","author":"Shale","year":"2008","journal-title":"Gut"},{"key":"R7-11-20210305","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0016-5085(93)90883-E","article-title":"Growth failure in children with inflammatory bowel disease: a prospective study.","volume":"105","author":"Motil","year":"1993","journal-title":"Gastroenterology"},{"key":"R8-11-20210305","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"R9-11-20210305","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1542\/peds.2009-3289","article-title":"Defensin-barbed innate immunity: clinical associations in the pediatric population.","volume":"125","author":"Underwood","year":"2010","journal-title":"Pediatrics"},{"key":"R10-11-20210305","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors.","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"R11-11-20210305","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0376-8716(00)00181-2","article-title":"Opioids, opioid receptors, and the immune response.","volume":"62","author":"McCarthy","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R12-11-20210305","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0026-895X(25)09932-8","article-title":"Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.","volume":"45","author":"Raynor","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R13-11-20210305","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20071689","article-title":"CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer.","volume":"412","author":"Parenty","year":"2008","journal-title":"Biochem J"},{"key":"R14-11-20210305","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd1852","article-title":"Chemokines: integrators of pain and inflammation.","volume":"4","author":"White","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"R15-11-20210305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cellimm.2007.09.008","article-title":"Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression.","volume":"252","author":"Finley","year":"2008","journal-title":"Cell Immunol"},{"key":"R16-11-20210305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1471-4906(03)00003-6","article-title":"Opioid G protein-coupled receptors: signals at the crossroads of inflammation.","volume":"24","author":"Rogers","year":"2003","journal-title":"Trends Immunol"},{"key":"R17-11-20210305","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/15476910802131469","article-title":"The opioid antagonist naltrexone improves murine inflammatory bowel disease.","volume":"5","author":"Matters","year":"2008","journal-title":"J Immunotoxicol"},{"key":"R18-11-20210305","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-dose naltrexone therapy improves active Crohns disease.","volume":"102","author":"Smith","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R19-11-20210305","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohns disease: a randomized placebo-controlled trial.","volume":"56","author":"Smith","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R20-11-20210305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohns disease activity index.","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R21-11-20210305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/jcp.0b13e3180337fcb","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and current depression.","volume":"27","author":"Petrakis","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R22-11-20210305","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/BF01333706","article-title":"A clinical scoring system for chronic inflammatory bowel disease in children.","volume":"24","author":"Lloyd-Still","year":"1979","journal-title":"Dig Dis Sci"},{"key":"R23-11-20210305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohns-disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"R24-11-20210305","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00005176-200210000-00018","article-title":"The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease.","volume":"35","author":"Otley","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R25-11-20210305","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(86)91196-7","article-title":"Naltrexone and hepatotoxicity.","volume":"1","author":"Mitchell","year":"1986","journal-title":"Lancet"},{"key":"R26-11-20210305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.alcohol.2006.05.003","article-title":"Study of hepatotoxicity of naltrexone in the treatment of alcoholism.","volume":"38","author":"Yen","year":"2006","journal-title":"Alcohol"},{"key":"R27-11-20210305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5040","article-title":"Quality-of-life measures in chronic diseases of childhood.","volume":"5","author":"Eiser","year":"2001","journal-title":"Health Technol Assess"},{"key":"R28-11-20210305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00054725-200502000-00013","article-title":"A review of activity indices and end points for clinical trials in children with Crohns disease.","volume":"11","author":"Griffiths","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"R29-11-20210305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohns Relapse Prevention Trial Study Group.","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"R30-11-20210305","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/00005176-199904001-00009","article-title":"Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type.","volume":"28","author":"Griffiths","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R31-11-20210305","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohns disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-11-20210305","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/j.1572-0241.2005.00256.x","article-title":"Narcotic use in patients with Crohns disease.","volume":"100","author":"Cross","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R33-11-20210305","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0006-8993(99)02446-4","article-title":"Enhanced analgesic potency and reduced tolerance of morphine in 129SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions.","volume":"856","author":"Crain","year":"2000","journal-title":"Brain Res"},{"issue":"suppl 1","key":"R34-11-20210305","doi-asserted-by":"crossref","first-page":"i91","DOI":"10.1136\/gut.51.suppl_1.i91","article-title":"Centrally acting agents and visceral sensitivity.","volume":"51","author":"Fioramonti","year":"2002","journal-title":"Gut"},{"key":"R35-11-20210305","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1046\/j.1365-2036.2002.01320.x","article-title":"Naloxone treatment for irritable bowel syndromea randomized controlled trial with an oral formulation.","volume":"16","author":"Hawkes","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-11-20210305","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1007\/s10620-006-9289-8","article-title":"Low-dose naltrexone for the treatment of irritable bowel syndrome: a pilot study.","volume":"51","author":"Kariv","year":"2006","journal-title":"Dig Dis Sci"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0b013e3182702f2b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T09:55:55Z","timestamp":1745229355000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201304000-00011"}},"subtitle":["A Pilot Study"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e3182702f2b","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}